



## How biotech IPOs performed in the third quarter

RayzeBio and Neumora recently priced high-profile offerings, while a handful of other drugmakers have joined the queue, signalling a potentially busier end to the year.

Published Oct. 3, 2023



Gwendolyn Wu  
Reporter

*The Nasdaq MarketSite is seen on October 12, 2022 in New York City. Michael M. Santiago via Getty Images*

Initial public offerings may slowly be coming back to the biotechnology sector.

Eight biotech companies priced IPOs from July through the end of September, raising \$1.1 billion in total, according to data compiled by BioPharma Dive. That compares to four in the second quarter, which brought in about \$580 million. (Kenvue, J&J's consumer division, also completed an IPO in May as part of a spinout.)

A handful of other companies are lining up to test the waters, too,

## Continue reading for free

Sign up for our daily newsletter to access this article.

*Already a subscriber? Sign in with your email above.*